# Freenome Inc. (FRNM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.31, market value $1.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Freenome Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.

## Profitability
- **Return on equity: -17.5%**. Return on equity is negative because earnings are negative.

## Financial health
- **Current ratio: 0.40** (quick 0.40). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.

## Dividends
- **Dividend: none**. Freenome Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Freenome Inc.; the consensus is strong_buy, with an average price target of $18.00 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 54.6%** (YTD 25.2%, 3-mo 46.8%). The shares are up 54.6% over twelve months including dividends.
- **From 52-week high: -5.0%** (63.9% above the low). Trading 5% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 75**. An RSI of 75 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.30** (volatility 38%). Beta of 0.30 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=FRNM · Page: https://foliofundamentals.com/stocks/frnm

Not investment advice.